Startseite New Paradigms for Growth Hormone Treatment in the 21st Century: Prediction Models
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

New Paradigms for Growth Hormone Treatment in the 21st Century: Prediction Models

Paediatric Endocrinology Section, University Children’s Hospital, Tubingen, Germany
  • M.B. Ranke
Veröffentlicht/Copyright: 22. Juli 2014

ABSTRACT

Inconsistent and sometimes disappointing final height outcomes in studies in which exogenous growth hormone (GH) was given to children with short stature resulting from various causes have led to attempts to determine the factors that influence responsiveness to GH. Many such factors have been identified, including the genetically determined height potential of the child, the height deficit, current and perinatal auxological and biological factors, and, importantly, GH treatment modalities. These factors vary depending on the cause of the growth failure and during the course of childhood and treatment with GH. Data from welldefined large cohorts can be entered into multiple regression analyses to derive algorithms describing the variation in growth response during a defined period and the influence on this of various factors. Pharmacoepidemiologic surveys have been particularly useful in this regard. Algorithms with low-error SD values, which have included the dose of GH as a variable, can be used to predict the response to a putative GH dose in a similar cohort or in an individual over an equivalent period. A sequential series of such algorithms can be integrated to form a predictive model. Such a model can be used for planning a course of treatment, but the patient data required for entry into the model should be easily obtainable if the model is to have widespread utility. The development of such models will allow GH treatment to be better individualized and optimized for growth and cost outcomes. Growth prediction models will facilitate realistic expectations and will permit stepwise goals to be set and monitored.

Published Online: 2014-07-22
Published in Print: 2000-12-01

© 2014 by Walter de Gruyter Berlin/Boston

Artikel in diesem Heft

  1. Titelei
  2. TABLE OF CONTENTS
  3. Foreword
  4. What Happens When Growth Hormone is Discontinued at Completion of Growth? Metabolic Aspects
  5. Growth Hormone Deficiency and Peak Bone Mass
  6. Optimal Strategy for Management of Pituitary Disease in the Growth Hormone-Deficient Teenager
  7. Ethical Dilemmas in Pediatric Endocrinology: Growth Hormone for Short Normal Children
  8. Evidence-Based Approach to Growth Hormone Replacement Therapy in Adults, with Special Emphasis on Body Composition
  9. Evidence-Based Growth Hormone Therapy Prediction Models
  10. New Paradigms for Growth Hormone Treatment in the 21st Century: Prediction Models
  11. Role of Insulin-like Growth Factor Monitoring in Optimizing Growth Hormone Therapy
  12. Knockout Mice Challenge Our Concepts of Glucose Homeostasis and the Pathogenesis of Diabetes Mellitus
  13. Type 2 Diabetes Mellitus in Children: Pathophysiology and Risk Factors
  14. Emergence of Type 2 Diabetes Mellitus in Children: Epidemiological Evidence
  15. Treatment of Type 2 Diabetes Mellitus in Children and Adolescents
  16. Diagnosis of Maturity-Onset Diabetes of the Young in the Pediatric Diabetes Clinic
  17. Thrifty Genotypes and Phenotypes in the Pathogenesis of Type 2 Diabetes Mellitus
  18. Estradiol: A Protective Factor in the Adult Brain
  19. Estrogen Treatment and Estrogen Suppression: Metabolic Effects in Adolescence
  20. Estrogen, Bone, Growth and Sex: A Sea Change in Conventional Wisdom
  21. Route-Dependent Endocrine and Metabolic Effects of Estrogen Replacement Therapy
  22. Telomerase and the Cellular Lifespan: Implications for the Aging Process
  23. Human Aging and Progeria
  24. A Role for the Somatotropic Axis in Neural Development, Injury and Disease
  25. Hypothalamic Growth Hormone-Insulin-like Growth Factor-I Axis across the Human Life Span
  26. The Lost Voice: A History of the Castrato
  27. SELECTED POSTER ABSTRACTS
  28. GROWTH. FETAL GROWTH. SGA
  29. SYNDROMES: TURNER. PRADER-WILLI. NOONAN. PHP. OTHERS
  30. GHD. HYPOPITUITARISM. KIGS
  31. METABOLIC. GENETIC. ADULT. ACROMEGALY
  32. GH. IGF. IGFBPs
  33. GROWTH IN SYSTEMIC DISEASE. CRI. RICKETS. STEROIDS
Heruntergeladen am 8.9.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpem-2000-s609/html
Button zum nach oben scrollen